Breaking News, Collaborations & Alliances

Merck, AstraZeneca in WEE1 License Agreement

Merck to receive $50 million upfront

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck and AstraZeneca have entered a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase MK-1775, currently in Phase IIa studies in combination with standard-of-care for the treatment of certain types of ovarian cancer. AstraZeneca will pay $50 million upfront and Merck will be eligible to receive future development and regulatory milestones, as well as royalties on sales. AZ will be responsible for all future clinical development, manufacturing and marketing. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters